Erasca Teams With Merck on AURORAS-1 Cancer Study

MT Newswires Live05-11

Erasca (ERAS) has entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors, the company said Monday.

Under the agreement, Erasca will sponsor the AURORAS-1 clinical proof-of-concept study, while Merck will supply Keytruda at no cost.

The trial will assess whether Erasca's ERAS-0015, a pan-RAS molecular glue, can enhance PD-1 blockade by reducing tumor-induced immune suppression and improving response durability in RAS/MAPK-driven cancers, the company said.

Shares of Erasca were up 4.7% in premarket activity Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment